Hepatitis C virus infection dynamics, treatment, and lipid nanoparticle–mediated infection in humanized liver chimeric mouse models
Science Advances · 29.05.2026 · 12 (22)
DOI: 10.1126/sciadv.aef1160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 29.05.2026. Verfasst von Seung Bum Park und 13 weiteren Autor:innen. Beteiligte Einrichtung: Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD 20892, U…. Hauptthemen laut MEDLINE: Hepatitis C, Hepacivirus, Nanoparticles, Liver. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Danish Cancer Society Research Center, Canadian Institutes of Health Research, Stavros Niarchos Foundation.
Abstract (Originalsprache)
A major challenge in hepatitis C virus (HCV) research is the lack of an in vivo model that supports robust infection, antiviral testing, and vaccine development. The humanized liver chimeric mouse models support high-level viremia from various HCV sources, although they lack an immune system. Here, we used Fah −/− /Rag2 −/− /Il2rg −/− (FRG) and urokinase-type plasminogen activator–severe combined immunodeficiency ( uPA -SCID) mice engrafted with primary human hepatocytes to investigate HCV infection dynamics and evaluate lipid nanoparticle (LNP)–mediated delivery of full-length HCV RNA. Mice were inoculated with HCV-positive chimpanzee serum or LNP-encapsulated HCV RNA of various genotypes and developed viremia reaching 10 8 copies per milliliter. RNA-LNP–mediated infection mirrored serum-derived infection that was transmissible to naïve mice. Glecaprevir/pibrentasvir cleared viremia, and treated mice could be reinfected. The proportion of antibody-free HCV RNA in human serum correlated with infectivity. These findings demonstrate the utility of this model for studying HCV infection and treatment and highlight LNP-based RNA delivery as a scalable approach for generating standardized challenge inocula.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD 20892, USA.
- Li Ka Shing Institute of Virology, Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada.
- Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of C…
- Hepatic Pathogenesis Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, MD 20892, USA.
- Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.
- Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY 10065, USA.
ORCID-Profile: Seung Bum Park, Regina Umarova, Justin Shields, Laura Collignon, Kenn Holmbeck, Ji Hoon Oh, D Lorne Tyrrell, Jordan J Feld, Jens Bukh, Charles M Rice, T Jake Liang
Förderung
- Danish Cancer Society Research Center
- Canadian Institutes of Health Research
- Stavros Niarchos Foundation
- Li Ka Shing Institute of Virology, University of Alberta
- Novo Nordisk Foundation
- Independent Research Fund Denmark
- Sygeforsikringen “Danmark”
- Købmand Niels Erik Munch Pedersen Foundation
Zitieren
APA
Park, S. B., Sánchez-Meza, J., Umarova, R., Shields, J., Collignon, L., Sula, X., Holmbeck, K., Oh, J. H., Farci, P., Tyrrell, D. L., Feld, J. J., Bukh, J., Rice, C. M., & Liang, T. J. (2026). Hepatitis C virus infection dynamics, treatment, and lipid nanoparticle–mediated infection in humanized liver chimeric mouse models. Science Advances, 12(22). https://doi.org/10.1126/sciadv.aef1160
Vancouver
Park SB, Sánchez-Meza J, Umarova R, Shields J, Collignon L, Sula X, et al. Hepatitis C virus infection dynamics, treatment, and lipid nanoparticle–mediated infection in humanized liver chimeric mouse models. Science Advances. 2026;12(22). doi:10.1126/sciadv.aef1160
BibTeX
@article{Park2026,
author = {Park, Seung Bum and Sánchez-Meza, Jaime and Umarova, Regina and Shields, Justin and Collignon, Laura and Sula, Xhuliana and Holmbeck, Kenn and Oh, Ji Hoon and Farci, Patrizia and Tyrrell, D Lorne and Feld, Jordan J and Bukh, Jens and Rice, Charles M and Liang, T Jake},
title = {Hepatitis C virus infection dynamics, treatment, and lipid nanoparticle–mediated infection in humanized liver chimeric mouse models},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {22},
doi = {10.1126/sciadv.aef1160}
}
EUVIMED